Fiat Chrysler Automobiles NV

These large companies lack economic moats and have negative moat trends--but we think they’re attractive nonetheless.

These stocks are trading in 5-star range but carry very high uncertainty.

Our analysts increased their fair value estimates on these stocks by more than 10% in June.

Ford and GM will remain the long-term heavyweights in the full-size pickup segment, but Ram should see the most growth this year.

We see no winners if free trade ends.

Industrials are the second-most-expensive sector we cover, but these picks can reward investors.

Despite a general premium to our fair value estimates in the sector, we still see several opportunities for investors.

These names all gained more than 10% during the past three months yet remain undervalued by our metrics.

We think the automaker is trading at a compelling discount to our fair value estimate.

Home improvement retailers are on a roll, with Lowe's lagging Home Depot. Plus, opportunity amid legal woes for Fiat Chrysler, and Raytheon looks solid for defense.

There’s more to the auto industry than Tesla.

Sector fundamentals are unexciting and valuations are elevated, but a few names show promise.

Defense is likely to be the clearest beneficiary, with a mixed impact for other sectors.

These stocks are undervalued based on a half-dozen valuation metrics.

We put this week’s disappointing auto and job numbers in perspective. Plus, fair value changes for two utilities after an outrageously priced deal.

Market participants are instead cheering a rise in oil prices and the fact that earnings season could be a lot worse.

Whether you need to fill a hole in your retirement portfolio or want to find a world-class company at a bargain-basement stock price, a trio of Morningstar specialists share their shopping lists of topnotch candidates.

Morningstar's Russ Kinnel, Ben Johnson, and Elizabeth Collins discuss their favorite investment ideas among mutual funds, ETFs, and stocks.

Some fears are overblown, leading to attractive valuations in financial services and consumer cyclical.

Shares the beleaguered pharma firm may look cheap, but investors should remain very cautious. Meanwhile, Berkshire pulls off decent results under less-than-ideal circumstances.